8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 4, 2021

Elanco Animal Health Incorporated

(Exact name of registrant as specified in its charter)

Indiana	001-38661	82-5497352
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2500 Innovation Way Greenfield, Indiana (Address of principal executive offices) 46140 (Zip Code)

Registrant’s telephone number, including area code: (877) 352-6261

Not Applicable

(Former Name or Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, no par value	ELAN	New York Stock Exchange
5.00% Tangible Equity Units	ELAT	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

¨ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events

On June 4, 2021, Elanco Animal Health Incorporated issued a press release announcing the hiring of Marcela A. Kirberger as general counsel and corporate secretary. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press Release issued by Elanco Animal Health Incorporated, dated June 4, 2021
104.1	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Elanco Animal Health Incorporated
Date: June 4, 2021	By:	/s/ Todd Young
		Name:  Todd Young
		Title:  Executive Vice President and Chief Financial Officer

EX-99.1

Exhibit 99.1

Investor Contact: Tiffany Kanaga, +1.302.897.0668 tiffany.kanaga@elancoah.com

Media Contact: Colleen Parr Dekker, +1.317.989.7011 colleen.dekker@elancoah.com

FOR IMMEDIATE RELEASE

Elanco Announces Addition of Marcela A. Kirberger as General Counsel and Corporate Secretary

Kirberger brings leadership experiences at both U.S. and German based companies to Elanco

Greenfield, Ind. (June 4, 2021) – Today, Elanco Animal Health Incorporated (NYSE: ELAN) named Marcela A. Kirberger as general counsel and corporate secretary. She joins the Elanco Executive Committee at the company’s Greenfield, Indiana-based headquarters on June 22.

Kirberger will have responsibility for all of Elanco’s legal functions. She joins the company with more than 20 years of corporate legal experience advising and leading companies through transformation to address evolving internal, national, and international challenges.

“Marcela is a clear fit for Elanco, with the right mix of executive leadership experiences at U.S. and German based companies,” said Jeff Simmons, president and chief executive officer of Elanco. “Her wide-ranging expertise in regulated, pharma, and over-the-counter in the human health sector complements our experienced animal health executive team, continuing to strengthen the management of key functional areas, such as Legal.”

Most recently, Kirberger was general counsel and corporate secretary at the North American headquarters of Roche Diagnostics, where she had executive responsibility for the Legal function, overseeing the areas of Commercial, Compliance, Litigation, Legal Regulatory Risk, Privacy, Operations and Labor and Employment. As a member of the company’s leadership team, she helped lead culture transformation and COVID-19 crisis management efforts at the company. Before Roche, she spent five years at German-based Leica Microsystems and Sandoz International in roles such as global general counsel, chief compliance officer, and global head of Legal for the Sandoz Biopharmaceuticals business unit. She also spent eight years in various U.S. and regional legal roles within different Novartis-owned companies. She began her career as a securities lawyer at Lowenstein Sandler PC in New Jersey, advising clients in securities class actions and shareholder litigation.

“As a leading animal health company, I was instantly drawn to Elanco, its vision, and its strong culture at a pivotal time for the company and the Legal function,” said Kirberger. “The critical importance of healthy animals to people and the planet has never been more evident than in the past year, so I’m looking forward to joining this growing industry and company to make a positive impact.”

With an interest in growing Indiana's life sciences industry, Kirberger has served as a board member of Indianapolis-based BioCrossroads for nearly two years alongside 20 public and private sector board members to facilitate investments in biotech start-ups, build growth companies, and promote education across technology and life sciences in Indiana.

Kirberger holds Juris Doctor degrees from Catholic University of Argentina School of Law and Rutgers University School of Law.

ABOUT ELANCO ANIMAL HEALTH

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ ESG/Sustainability framework – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.

Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

© 2021 Elanco or its affiliates.

###

XML

Cover	Jun. 04, 2021
Entity Listings [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 04, 2021
Entity File Number	001-38661
Entity Registrant Name	Elanco Animal Health Incorporated
Entity Central Index Key	0001739104
Entity Tax Identification Number	82-5497352
Entity Incorporation, State or Country Code	IN
Entity Address, Address Line One	2500 Innovation Way
Entity Address, City or Town	Greenfield
Entity Address, State or Province	IN
Entity Address, Postal Zip Code	46140
City Area Code	877
Local Phone Number	352-6261
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member]
Entity Listings [Line Items]
Title of 12(b) Security	Common stock, no par value
Trading Symbol	ELAN
Security Exchange Name	NYSE
5.00 Percent Tangible Equity Units [Member]
Entity Listings [Line Items]
Title of 12(b) Security	5.00% Tangible Equity Units
Trading Symbol	ELAT
Security Exchange Name	NYSE